Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138454 | 1.00 | P2RX7 (0.51) | P2RX7ABCB11 | |
| SCHEMBL6449078 | 0.90 | P2RX7 (0.63) | P2RX7ABCB11 | |
| SCHEMBL5076144 | 0.90 | P2RX7 (0.63) | P2RX7ABCB11 | |
| SCHEMBL5710576 | 0.90 | P2RX7 (0.63) | P2RX7ABCB11 | |
| Hydrochloric Acid SCHEMBL5710666 | 0.89 | P2RX7 (0.62) | P2RX7ABCB11 | |
| Hydrochloric Acid SCHEMBL5710696 | 0.89 | P2RX7 (0.62) | P2RX7ABCB11 | |
| SCHEMBL5821316 | 0.88 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL4039802 | 0.88 | P2RX7 (0.58) | P2RX7 | |
| SCHEMBL7077845 | 0.85 | P2RX7 (0.62) | P2RX7ABCB11 | |
| SCHEMBL5710711 | 0.81 | P2RX7 (0.65) | P2RX7ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007501270-A | — | — | 2007-01-25 | — | — | JP | claimed |
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| EP-1633401-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | claimed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| EP-1644042-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1633401-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR ALPHA | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105796-A1 | A PHARMACEUTICAL COMPOSITION CONTAINING A P2X7 RECEPTOR ANTAGONIST AND METHOTREXATE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105798-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010497-A1 | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.